Vimarsana
Biggest News Aggregation in the World

Sandip Mitra News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sandip Mitra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sandip Mitra Today - Breaking & Trending Today

Invizius's Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study - Vimarsana News

Invizius's Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study

/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, announces that eight...

Invizius's Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study - Vimarsana News

Invizius's Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study

Study demonstrated safety and tolerability of H-Guard®, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis.Encouraging biomarker data positions H-Guard for upcoming Acute Kidney Injury (AKI) trial focused on reducing complement mediated renal tubu...

Invizius Receives MHRA Approval to Commence First-in-Human Clinical Study of H-Guard® Priming Solution - Vimarsana News

Invizius Receives MHRA Approval to Commence First-in-Human Clinical Study of H-Guard® Priming Solution

/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and...

Amid doubts, Govt sets up panel to review conduct of surveys - Vimarsana News

Amid doubts, Govt sets up panel to review conduct of surveys

The committee has also been mandated to provide guidance to conduct pilot surveys/ pre-testing, if necessary, before finalising schedules for data collection.

Invizius announces 'Angry Blood' Haemodialysis Study and recruits its 300th patient - Vimarsana News

Invizius announces 'Angry Blood' Haemodialysis Study and recruits its 300th patient

/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and...